Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-90001 in NASH with liver fibrosis
2018-004431-79Phase 2Unknown
- Sponsor
- Celgene Corporation
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis comparing CC-90001 with Placebo (2 arms). Primary endpoint: Liver fibrosis score. Status: unknown.
02
Drugs
CC-90001
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on 2018-004431-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004431-79.